News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Hua Medicine Begins Phase I Trial of Novel Diabetes Treatment


9/6/2013 12:32:14 PM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

by Richard Daverman, PhD

September 6, 2013 -- Hua Medicine has begun a China Phase I clinical trial of a novel Glucokinase activator treatment for diabetes 2. The CFDA gave HMS5552, as the Hua drug is known, the designation of type 1.1 novel drug because no drug of the Glucokinase activator class has been approved anywhere in the world. Hua in-licensed China rights to the drug from Roche two years ago. In a statement, Dr. Li Chen, CEO of Hua Medicine, noted that it was a significant milestone for Hua to start clinical development in China of an innovative diabetes treatment that is intended for the world’s market. More details....

Help employers find you! Check out all the jobs and post your resume.

Read at ChinaBio Today

comments powered by Disqus
 
 
Diabetes

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES